Vera Therapeutics, Inc. (VERA) Stock
VERA has an Alpha Score of 24 out of 100 (poor), computed on Nov 6, 2026 from 2 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported VERA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $11.99M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is VERA's Alpha Score?
How it works →Alpha Score of 23 reflects poor overall profile with poor momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own VERA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 280K | $11.99M | -39% |
| Millennium Management Israel Englander | 279K | $11.96M | -5% |
| D.E. Shaw David Shaw | 75K | $3.20M | +1255% |
| Point72 Steve Cohen | 41K | $1.74M | -97% |
| Marshall Wace | 8K | $323.2K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Vera Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 15, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 18.5K | $685K |
| Sep 2, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 18.5K | $650K |
| Jul 7, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 1.0K | $41K |
| Jul 7, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 32.5K | $1.4M |
| Jul 7, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 10.5K | $450K |
| Jul 7, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 2.2K | $96K |
| Jun 23, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 18.4K | $698K |
| Jun 23, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 88 | $3K |
| May 12, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 14.2K | $521K |
| May 12, 26 | Fordyce Marshall | PRESIDENT AND CEO | SELL | 4.3K | $159K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are VERA's key statistics?
Key statistics as of Nov 9, 2026
VERA price chart
Powered by TradingViewWhat does Vera Therapeutics, Inc. do?
Vera Therapeutics Inc. is a biotechnology company engaged in the research and development of transformative therapies aimed at treating immune-mediated diseases. The primary focus of Vera Therapeutics is to address unmet medical needs, particularly in the treatment of conditions such as immunoglobulin A nephropathy (IgAN), a kidney disorder that can lead to irreversible damage and renal failure. The company's lead asset, atacicept, is a novel, biologic therapeutic that targets specific pathways implicated in the pathogenesis of autoimmune diseases. Vera Therapeutics operates at the forefront of the biotechnology sector, a field characterized by rapid innovation and significant impact on healthcare and disease management. By advancing clinical trials and pursuing regulatory approval for their therapies, Vera Therapeutics contributes significantly to the potential revolutionizing of treatment options for patients with chronic conditions. Founded with a commitment to improving patients' lives, Vera Therapeutics plays a crucial role in expanding the biotech landscape, aiming to bring new hope and effective solutions to markets historically underserved by traditional pharmaceutical approaches.